228 related articles for article (PubMed ID: 27974200)
1. Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin.
Adhikari AS; Kooiker KB; Sarkar SS; Liu C; Bernstein D; Spudich JA; Ruppel KM
Cell Rep; 2016 Dec; 17(11):2857-2864. PubMed ID: 27974200
[TBL] [Abstract][Full Text] [Related]
2. Myosin motor domains carrying mutations implicated in early or late onset hypertrophic cardiomyopathy have similar properties.
Vera CD; Johnson CA; Walklate J; Adhikari A; Svicevic M; Mijailovich SM; Combs AC; Langer SJ; Ruppel KM; Spudich JA; Geeves MA; Leinwand LA
J Biol Chem; 2019 Nov; 294(46):17451-17462. PubMed ID: 31582565
[TBL] [Abstract][Full Text] [Related]
3. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.
Vander Roest AS; Liu C; Morck MM; Kooiker KB; Jung G; Song D; Dawood A; Jhingran A; Pardon G; Ranjbarvaziri S; Fajardo G; Zhao M; Campbell KS; Pruitt BL; Spudich JA; Ruppel KM; Bernstein D
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34117120
[TBL] [Abstract][Full Text] [Related]
4. β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity.
Adhikari AS; Trivedi DV; Sarkar SS; Song D; Kooiker KB; Bernstein D; Spudich JA; Ruppel KM
Nat Commun; 2019 Jun; 10(1):2685. PubMed ID: 31213605
[TBL] [Abstract][Full Text] [Related]
5. Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay.
Debold EP; Schmitt JP; Patlak JB; Beck SE; Moore JR; Seidman JG; Seidman C; Warshaw DM
Am J Physiol Heart Circ Physiol; 2007 Jul; 293(1):H284-91. PubMed ID: 17351073
[TBL] [Abstract][Full Text] [Related]
6. The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin.
Sarkar SS; Trivedi DV; Morck MM; Adhikari AS; Pasha SN; Ruppel KM; Spudich JA
Sci Adv; 2020 Apr; 6(14):eaax0069. PubMed ID: 32284968
[TBL] [Abstract][Full Text] [Related]
7. Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy.
Kawana M; Sarkar SS; Sutton S; Ruppel KM; Spudich JA
Sci Adv; 2017 Feb; 3(2):e1601959. PubMed ID: 28246639
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.
Roopnarine O; Leinwand LA
Biophys J; 1998 Dec; 75(6):3023-30. PubMed ID: 9826622
[TBL] [Abstract][Full Text] [Related]
9. Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.
Tang W; Unrath WC; Desetty R; Yengo CM
J Biol Chem; 2019 Nov; 294(46):17314-17325. PubMed ID: 31578282
[TBL] [Abstract][Full Text] [Related]
10. Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.
Spudich JA
Pflugers Arch; 2019 May; 471(5):701-717. PubMed ID: 30767072
[TBL] [Abstract][Full Text] [Related]
11. Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin.
Spudich JA; Aksel T; Bartholomew SR; Nag S; Kawana M; Yu EC; Sarkar SS; Sung J; Sommese RF; Sutton S; Cho C; Adhikari AS; Taylor R; Liu C; Trivedi D; Ruppel KM
J Exp Biol; 2016 Jan; 219(Pt 2):161-7. PubMed ID: 26792326
[TBL] [Abstract][Full Text] [Related]
12. Myosin regulatory light chain phosphorylation enhances cardiac β-myosin in vitro motility under load.
Karabina A; Kazmierczak K; Szczesna-Cordary D; Moore JR
Arch Biochem Biophys; 2015 Aug; 580():14-21. PubMed ID: 26116789
[TBL] [Abstract][Full Text] [Related]
13. Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function.
Morck MM; Bhowmik D; Pathak D; Dawood A; Spudich J; Ruppel KM
Elife; 2022 Jun; 11():. PubMed ID: 35767336
[TBL] [Abstract][Full Text] [Related]
14. Hypertrophic cardiomyopathy R403Q mutation in rabbit β-myosin reduces contractile function at the molecular and myofibrillar levels.
Lowey S; Bretton V; Joel PB; Trybus KM; Gulick J; Robbins J; Kalganov A; Cornachione AS; Rassier DE
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):11238-11243. PubMed ID: 30322937
[TBL] [Abstract][Full Text] [Related]
15. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium.
Palmer BM; Fishbaugher DE; Schmitt JP; Wang Y; Alpert NR; Seidman CE; Seidman JG; VanBuren P; Maughan DW
Am J Physiol Heart Circ Physiol; 2004 Jul; 287(1):H91-9. PubMed ID: 15001446
[TBL] [Abstract][Full Text] [Related]
16. Tail length and E525K dilated cardiomyopathy mutant alter human β-cardiac myosin super-relaxed state.
Duno-Miranda S; Nelson SR; Rasicci DV; Bodt SML; Cirilo JA; Vang D; Sivaramakrishnan S; Yengo CM; Warshaw DM
J Gen Physiol; 2024 Jun; 156(6):. PubMed ID: 38709176
[TBL] [Abstract][Full Text] [Related]
17. Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes.
Alamo L; Ware JS; Pinto A; Gillilan RE; Seidman JG; Seidman CE; Padrón R
Elife; 2017 Jun; 6():. PubMed ID: 28606303
[TBL] [Abstract][Full Text] [Related]
18. Mavacamten decreases maximal force and Ca
Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW
Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.
Hayashi T
Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552
[TBL] [Abstract][Full Text] [Related]
20. The R249Q hypertrophic cardiomyopathy myosin mutation decreases contractility in Drosophila by impeding force production.
Bell KM; Kronert WA; Huang A; Bernstein SI; Swank DM
J Physiol; 2019 May; 597(9):2403-2420. PubMed ID: 30950055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
